Form 4: Boundless Bio Director Jennifer Lew Receives Stock Options

Director Jennifer Lew was granted 32,000 stock options in Boundless Bio, Inc. as part of a standard equity compensation arrangement.

Summary

• Jennifer Lew, a Director at Boundless Bio, Inc., was granted 32,000 stock options on June 15, 2026.
• The options have an exercise price of $1.40 per share.
• The options are set to expire on June 14, 2036.
• The grant vests in equal monthly installments over 12 months, contingent on continued board service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in minor potential dilution for existing shareholders upon future exercise of options.

Risks

• Vesting is subject to the reporting person's continued service on the board of directors.

Future Outlook

The options vest over a 12-month period starting June 15, 2026, with an accelerated vesting provision tied to the next annual stockholders' meeting.

Industry Context

StockSavvy.ai notes that equity grants for board members are standard practice in the biotechnology sector to ensure alignment between leadership and corporate performance goals.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard corporate governance practices for small-cap biotech firms.
• The 12-month vesting schedule is a common retention mechanism for board members in the industry.

Stakeholder Impact

• Minor dilution impact on shareholders upon potential future exercise of options.

Next Steps

• Vesting of options in monthly installments over the next 12 months.

Key Dates

Keywords

Boundless Bio, BOLD, Director Compensation, Stock Options, Insider Transaction, SEC Form 4